Francois Gaudet

USPTO Granted Patents = 11 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 7.5

ph-index = 4

Forward Citations = 32(Granted Patents)

Location History:

Princeton, NJ (US) (2017 - 2024)
Spring House, PA (US) (2018 - 2024)

Company Filing History:

7 out of 410

Janssen Biotech, Inc.

patents

4 out of 2,076

Janssen Pharmaceutica Nv

where one patent can have more than one assignee

Years Active: 2017-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12077592 - GPRC5D chimeric antigen receptors and cells expressing the same (2024-09-03),

2. 12065500 - Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics (2024-08-20),

3. 12012461 - Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics (2024-06-18),

4. 11884722 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2024-01-30),

5. 11685777 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2023-06-27),

6. 11603405 - Anti-CD3 antibodies and uses thereof (2023-03-14),

7. 11466082 - Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof (2022-10-11),

8. 10844122 - Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof (2020-11-24),

9. 10562968 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2020-02-18),

10. 10072088 - Anti-BCMA antibodies and uses thereof (2018-09-11),

11. 9850310 - CD123 binding agents and uses thereof (2017-12-26),

Title: Innovations and Contributions of Inventor Francois Gaudet

Introduction: Francois Gaudet, based in Princeton, NJ, is a notable inventor recognized for his contributions to the field of cancer treatment. With a remarkable portfolio, he holds 11 patents, showcasing his expertise and commitment to advancing medical technologies.

Latest Patents: Among his latest innovations, Gaudet has developed chimeric antigen receptors (CARs) that specifically target the G-protein coupled receptor, GPRC5D. This innovation provides a new approach to cancer treatment by utilizing immunoresponsive cells that express these CARs. Furthermore, he has disclosed methods aimed at enhancing the efficacy of T cell redirecting therapeutics for cancer treatment, representing a significant advancement in therapeutic techniques.

Career Highlights: Gaudet has worked with esteemed companies, including Janssen Biotech, Inc. and Janssen Pharmaceutica NV, where he has been instrumental in harnessing innovative technologies to drive forward cancer research and treatment.

Collaborations: Throughout his career, Gaudet has collaborated with talented professionals in the field, including peers like Ricardo Attar and Yingzhe Li. These collaborations have greatly enriched his work and contributed to the advancements in cancer therapies.

Conclusion: Francois Gaudet stands out as a dedicated inventor with significant contributions in the realm of cancer treatment. His patents and work with leading biopharmaceutical companies highlight his commitment to developing innovative solutions for complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.